Bladder Cancer, Version 2.2022 Featured Updates to the NCCN Guidelines

Academic Article

Abstract

  • The NCCN Guidelines for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer and other urinary tract cancers (upper tract tumors, urothelial carcinoma of the prostate, primary carcinoma of the urethra). These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines regarding the treatment of non–muscle-invasive bladder cancer, including how to treat in the event of a bacillus Calmette-Guérin (BCG) shortage; new roles for immune checkpoint inhibitors in non–muscle invasive, muscle-invasive, and metastatic bladder cancer; and the addition of antibody–drug conjugates for metastatic bladder cancer.
  • Digital Object Identifier (doi)

    Pubmed Id

  • 27159400
  • Author List

  • Flaig TW; Spiess PE; Abern M; Agarwal N; Bangs R; Boorjian SA; Buyyounouski MK; Chan K; Chang S; Friedlander T
  • Start Page

  • 866
  • End Page

  • 878
  • Volume

  • 20
  • Issue

  • 8